The American Journal of Medicine
Volume 122, Issue 12 , Pages 1071-1076 , December 2009

Management of Adult Jehovah's Witness Patients with Acute Bleeding

  • Kenrick Berend, MD, PhD

      Affiliations

    • Department of Medicine, St. Elisabeth Hospital, Willemstad, Curaçao, Netherlands Antilles
    • Corresponding Author InformationRequests for reprints should be addressed to Kenrick Berend, MD, PhD, Department of Medicine, St. Elisabeth Hospital, Breedestraat 193, Willemstad, Curaçao, Netherlands Antilles
    • ,
  • Marcel Levi, MD, PhD

      Affiliations

    • Department of Medicine, Academic Medical Center, University of Amsterdam, The Netherlands

References 

  1. Muramoto O. Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's Witnesses. BMJ. 2001;322:37–39
  2. In: The Watchtower. 1989 Mar 1;p. 6–7
  3. Chua R, Tham KF. Will “no blood” kill Jehovah Witnesses?. Singapore Med J. 2006;47:994–1002
  4. Harrington C. Father shunned by family for defying faith to save child. Canadian Press. Mar 11, 2002;
  5. Wilson P. Jehovah's Witness children: when religion and the law collide. Paediatr Nurs. 2005;17:34–37
  6. Lieberman JA, Weiskopf RB, Kelley SD, et al. Critical oxygen delivery in conscious humans is less than 7.3 ml O2×kg(−1)×min(−1). Anesthesiology. 2000;92:407–413
  7. Weiskopf RB, Kramer JH, Viele M, et al. Acute severe isovolemic anemia impairs cognitive function and memory in humans. Anesthesiology. 2000;92:1646–1652
  8. Ferzli GS, Hurwitz JB, Fiorillo MA, et al. Laparoscopic splenectomy in a Jehovah's Witness with profound anemia. Surg Endosc. 1997;11:850–851
  9. Ng KO, Chow LH, Wang CC, et al. Successful management of massive blood loss to extremely low hemoglobin in an elderly woman receiving spinal surgery. Acta Anaesthesiol Sin. 2000;38:89–92
  10. Meier DE, Back AL, Morrison RS. The inner life of physicians and care of the seriously ill. JAMA. 2001;286:3007–3014
  11. Smith S. The role of the court in ethical decision making. Clin Med. 2001;1:371–373
  12. Marsh JC, Bevan DH. Haematological care of the Jehovah's Witness patient. Br J Haematol. 2002;119:25–37
  13. Jehovah's Witnesses and Blood: A Physician's Guide to Saving Lives and Limiting Personal Liability. www.ajwrb.org/physicians/download.shtmlAccessed December 6, 2008
  14. Bodnaruk ZM, Wong CJ, Thomas MJ. Meeting the clinical challenge of care for Jehovah's Witnesses. Transfus Med Rev. 2004;18:105–116
  15. Vincent JL. Transfusion in the exsanguinating Jehovah's Witness patient—the attitude of intensive-care doctors. Eur J Anaesthesiol. 1991;8:297–300
  16. De Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med. 2001;29:1261–1267
  17. Trouwborst A, Hagenouw RR, Jeekel J, Ong GL. Hypervolaemic haemodilution in an anaemic Jehovah's Witness. Br J Anaesth. 1990;64:646–648
  18. Palmer K, Nairn M Guideline Development Group. Management of acute gastrointestinal blood loss: summary of SIGN guidelines. BMJ. 2008;337:a1832
  19. Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med. 2001;345:669–681
  20. Crew JP, Jephcott CR, Reynard JM. Radiation-induced haemorrhagic cystitis. Eur Urol. 2001;40:111–123
  21. Remonda L, Schroth G, Caversaccio M, et al. Endovascular treatment of acute and subacute hemorrhage in the head and neck. Arch Otolaryngol Head Neck Surg. 2000;126:1255–1262
  22. Munro MG, Mainor N, Basu R, et al. Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: A randomized controlled trial. Obstet Gynecol. 2006;108:924–929
  23. Levi M. Emergency reversal of antithrombotic treatment. Intern Emerg Med. 2009;4:137–145
  24. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222
  25. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literture. Am J Hematol. 2008;83:137–143
  26. DeZee KJ, Shimeall WT, Douglas KM, et al. Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med. 2006;166:391
  27. Fiore LD, Scola MA, Cantillon CE, Brophy MT. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis. 2001;11:175–183
  28. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;31:2301–2311
  29. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for the treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33:883–890
  30. Goldberg R, Drummond KJ. Recombinant activated factor VII for a warfarinised Jehovah's Witness with an acute subdural haematoma. J Clin Neurosci. 2008;15:1164–1166
  31. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8–15
  32. Mayer SA, Brun NC, Begtrup K, et al. FAST Trial Investigators Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127–2137
  33. Franchini M. The use of desmopressin as a hemostatic agent: a concise review. Am J Hematol. 2007;82:731–735
  34. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol. 2004;76:74–78
  35. Miller HJ, Hu J, Valentine JK, Gable PS. Efficacy and tolerability of intravenous ferric gluconate in the treatment of iron deficiency anemia in patients without kidney disease. Arch Intern Med. 2007;167:1327–1328
  36. Van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med. 2000;28:2773–2778
  37. Gannon CJ, Napolitano LM. Severe anemia after gastrointestinal hemorrhage in a Jehovah's Witness: new treatment strategies. Crit Care Med. 2002;30:1893–1895
  38. Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit Care Med. 1999;27:2346–2350
  39. De Andrade JR, Jove M, Landon G, et al. Baseline hemoglobin as a predictor of risk of transfusion and response to epoietin alfa in orthopedic surgery patients. Am J Orthop. 1996;25:533–542
  40. Remmers PA, Speer AJ. Clinical strategies in the medical care of Jehovah's Witnesses. Am J Med. 2006;119:1013–1018
  41. Ball AM, Winstead PS. Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. Pharmacotherapy. 2008;28:1383–1390
  42. Gannon CJ, Napolitano LM. Severe anemia after gastrointestinal hemorrhage in a Jehovah's Witness: new treatment strategies. Crit Care Med. 2002;30:1893–1895
  43. Eyster E, Bernene J. Nosocomial anemia. JAMA. 1973;223:73–74
  44. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults. N Engl J Med. 1986;314:1233–1235
  45. Levy JH. The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss. Expert Opin Biol Ther. 2003;3:509–517
  46. Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA. 2008;299:2304–2312

 Funding: None; no funding sources for this manuscript.

 Conflict of Interest: There are no conflicts of interest to disclose.

 Authorship: Both authors had access to the data and content of this manuscript and had a role in the writing of the manuscript.

PII: S0002-9343(09)00775-X

doi: 10.1016/j.amjmed.2009.06.028

The American Journal of Medicine
Volume 122, Issue 12 , Pages 1071-1076 , December 2009

Article Tools